JP2017511794A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017511794A5 JP2017511794A5 JP2016551246A JP2016551246A JP2017511794A5 JP 2017511794 A5 JP2017511794 A5 JP 2017511794A5 JP 2016551246 A JP2016551246 A JP 2016551246A JP 2016551246 A JP2016551246 A JP 2016551246A JP 2017511794 A5 JP2017511794 A5 JP 2017511794A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- amino
- compound
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 66
- 150000001875 compounds Chemical class 0.000 claims 42
- 125000000623 heterocyclic group Chemical group 0.000 claims 33
- 125000003545 alkoxy group Chemical group 0.000 claims 27
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 23
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 22
- -1 —S (O) m —R f Chemical group 0.000 claims 19
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 18
- 125000000547 substituted alkyl group Chemical group 0.000 claims 14
- 229910052736 halogen Inorganic materials 0.000 claims 13
- 125000001072 heteroaryl group Chemical group 0.000 claims 13
- 150000002367 halogens Chemical class 0.000 claims 12
- 125000001424 substituent group Chemical group 0.000 claims 12
- 150000003857 carboxamides Chemical class 0.000 claims 11
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 11
- 150000001204 N-oxides Chemical class 0.000 claims 9
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000012453 solvate Substances 0.000 claims 9
- 208000002193 Pain Diseases 0.000 claims 8
- 125000001188 haloalkyl group Chemical group 0.000 claims 7
- 229940124530 sulfonamide Drugs 0.000 claims 7
- 150000003456 sulfonamides Chemical class 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 125000004438 haloalkoxy group Chemical group 0.000 claims 6
- 230000036407 pain Effects 0.000 claims 6
- 125000003107 substituted aryl group Chemical group 0.000 claims 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 3
- 125000005518 carboxamido group Chemical group 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 claims 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 claims 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 claims 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 claims 1
- RGICCULPCWNRAB-UHFFFAOYSA-N 2-[2-(2-hexoxyethoxy)ethoxy]ethanol Chemical compound CCCCCCOCCOCCOCCO RGICCULPCWNRAB-UHFFFAOYSA-N 0.000 claims 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 claims 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 claims 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- BKZXMCAIWWDHSQ-JOCHJYFZSA-N 6-[(1S)-1,2-dihydroxyethyl]-4-[5-[4-(trifluoromethyl)phenyl]-3,4-dihydro-1H-isoquinolin-2-yl]pyridine-2-carboxamide Chemical compound O[C@H](CO)C1=CC(=CC(=N1)C(=O)N)N1CC2=CC=CC(=C2CC1)C1=CC=C(C=C1)C(F)(F)F BKZXMCAIWWDHSQ-JOCHJYFZSA-N 0.000 claims 1
- PDKJRCDTWHBSKE-UHFFFAOYSA-N 6-[5-[4-(trifluoromethyl)phenyl]-3,4-dihydro-1H-isoquinolin-2-yl]pyridine-2-carboxamide Chemical compound FC(C1=CC=C(C=C1)C1=C2CCN(CC2=CC=C1)C1=CC=CC(=N1)C(=O)N)(F)F PDKJRCDTWHBSKE-UHFFFAOYSA-N 0.000 claims 1
- HHIDIFCNHJJOIJ-AWEZNQCLSA-N 6-[[(2S)-1-amino-1-oxopropan-2-yl]amino]-2-(5-cyclohexyl-3,4-dihydro-1H-isoquinolin-2-yl)pyrimidine-4-carboxamide Chemical compound NC([C@H](C)NC1=CC(=NC(=N1)N1CC2=CC=CC(=C2CC1)C1CCCCC1)C(=O)N)=O HHIDIFCNHJJOIJ-AWEZNQCLSA-N 0.000 claims 1
- ZLMXMGFQERVQES-LBPRGKRZSA-N 6-[[(2S)-1-amino-1-oxopropan-2-yl]amino]-2-[5-[5-(trifluoromethyl)pyridin-2-yl]-3,4-dihydro-1H-isoquinolin-2-yl]pyrimidine-4-carboxamide Chemical compound NC([C@H](C)NC1=CC(=NC(=N1)N1CC2=CC=CC(=C2CC1)C1=NC=C(C=C1)C(F)(F)F)C(=O)N)=O ZLMXMGFQERVQES-LBPRGKRZSA-N 0.000 claims 1
- 208000008822 Ankylosis Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 206010008027 Cerebellar atrophy Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 206010023198 Joint ankylosis Diseases 0.000 claims 1
- 208000036626 Mental retardation Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- SBKIFLXSGDXZHF-UHFFFAOYSA-N N-(1,2,4-thiadiazol-5-yl)-6-[5-[4-(trifluoromethyl)phenyl]-3,4-dihydro-1H-isoquinolin-2-yl]pyridine-2-sulfonamide Chemical compound S1N=CN=C1NS(=O)(=O)C1=NC(=CC=C1)N1CC2=CC=CC(=C2CC1)C1=CC=C(C=C1)C(F)(F)F SBKIFLXSGDXZHF-UHFFFAOYSA-N 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 claims 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims 1
- 229940126208 compound 22 Drugs 0.000 claims 1
- 229940125833 compound 23 Drugs 0.000 claims 1
- 229940125961 compound 24 Drugs 0.000 claims 1
- 229940125846 compound 25 Drugs 0.000 claims 1
- 229940125851 compound 27 Drugs 0.000 claims 1
- 229940127204 compound 29 Drugs 0.000 claims 1
- 229940125877 compound 31 Drugs 0.000 claims 1
- 229940125878 compound 36 Drugs 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 208000014617 hemorrhoid Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 230000002197 limbic effect Effects 0.000 claims 1
- 238000002690 local anesthesia Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 238000009116 palliative therapy Methods 0.000 claims 1
- 230000001314 paroxysmal effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 238000000163 radioactive labelling Methods 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461939082P | 2014-02-12 | 2014-02-12 | |
| US61/939,082 | 2014-02-12 | ||
| PCT/US2015/015576 WO2015123398A1 (en) | 2014-02-12 | 2015-02-12 | Isoquinoline derivatives and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017511794A JP2017511794A (ja) | 2017-04-27 |
| JP2017511794A5 true JP2017511794A5 (enExample) | 2017-08-03 |
| JP6556154B2 JP6556154B2 (ja) | 2019-08-07 |
Family
ID=53800620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016551246A Active JP6556154B2 (ja) | 2014-02-12 | 2015-02-12 | イソキノリン誘導体及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10738026B2 (enExample) |
| EP (1) | EP3105217B1 (enExample) |
| JP (1) | JP6556154B2 (enExample) |
| CN (1) | CN106103422B (enExample) |
| AU (1) | AU2015217185B2 (enExample) |
| CA (1) | CA2939501C (enExample) |
| IL (1) | IL247252B (enExample) |
| WO (1) | WO2015123398A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10138207B2 (en) | 2012-11-09 | 2018-11-27 | Purdue Pharma, L.P. | Benzomorphan analogs and the use thereof |
| US9120786B2 (en) | 2013-03-04 | 2015-09-01 | Purdue Pharma, L.P. | Triazine carboxamides as sodium channel blockers |
| CA3082427A1 (en) | 2013-03-15 | 2014-09-25 | Purdue Pharma L.P. | Carboxamide derivatives and use thereof |
| CA2922567A1 (en) | 2013-08-26 | 2015-03-05 | Purdue Pharma L.P. | Azaspiro[4.5]decane derivatives and use thereof |
| US9828348B2 (en) | 2013-11-08 | 2017-11-28 | Purdue Pharma L.P. | Benzimidazole derivatives and use thereof |
| JP6337124B2 (ja) | 2013-12-23 | 2018-06-06 | パーデュー、ファーマ、リミテッド、パートナーシップ | インダゾール及びその使用 |
| US9656962B2 (en) | 2013-12-26 | 2017-05-23 | Purdue Pharma L.P. | Ring-contracted morphinans and the use thereof |
| WO2015097547A1 (en) | 2013-12-26 | 2015-07-02 | Purdue Pharma L.P. | 10-substituted morphinan hydantoins |
| WO2015097548A1 (en) | 2013-12-26 | 2015-07-02 | Purdue Pharma L.P. | 7-beta-alkyl analogs of orvinols |
| EP3087079B1 (en) | 2013-12-26 | 2019-04-03 | Purdue Pharma LP | Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans |
| WO2015099863A1 (en) | 2013-12-27 | 2015-07-02 | Purdue Pharma L.P. | 6-substituted and 7-substituted morphinan analogs and the use thereof |
| JP6526023B2 (ja) | 2014-01-24 | 2019-06-05 | パーデュー、ファーマ、リミテッド、パートナーシップ | ピリジン類及びピリミジン類並びにその使用 |
| JP2017521373A (ja) | 2014-05-27 | 2017-08-03 | パーデュー、ファーマ、リミテッド、パートナーシップ | スピロ環モルフィナン及びその使用 |
| CA2951697A1 (en) | 2014-06-13 | 2015-12-17 | Purdue Pharma L.P. | Azamophinan derivatives and use thereof |
| MA41125A (fr) | 2014-12-05 | 2017-10-10 | Purdue Pharma Lp | Dérivés de 6.7-cyclomorphinane et leur utilisation |
| CN110325516A (zh) | 2016-12-29 | 2019-10-11 | 米尼奥尔克斯治疗有限公司 | 杂芳基化合物和它们的用途 |
| WO2018125716A1 (en) | 2017-01-02 | 2018-07-05 | Purdue Pharma L.P. | Morphinan derivatives and use thereof |
| EP3589626B1 (en) * | 2017-03-03 | 2024-06-12 | National Taiwan University | 8-phenyl-isoquinolines and pharmaceutical composition thereof used in the treatment of irritable bowel syndrome |
| AU2018352695A1 (en) | 2017-10-19 | 2020-05-28 | Effector Therapeutics, Inc. | Benzimidazole-indole inhibitors of Mnk1 and Mnk2 |
| CN110372584A (zh) * | 2019-06-25 | 2019-10-25 | 南京普锐达医药科技有限公司 | 一种2,4-二氯-6-氰基嘧啶的合成方法 |
| IL314405A (en) * | 2022-01-18 | 2024-09-01 | Bsense Bio Therapeutics Ltd | Substances affecting the potassium channel and the TRPV1 channel and their uses |
| WO2023147063A2 (en) * | 2022-01-28 | 2023-08-03 | Opna Bio SA | Compounds and methods for yap/tead modulation and indications therefor |
| WO2024210578A1 (ko) * | 2023-04-05 | 2024-10-10 | 주식회사 바오밥에이바이오 | 헤테로비시클릭 화합물 및 그를 포함하는 약제학적 조성물 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001526648A (ja) | 1997-04-22 | 2001-12-18 | コセンシス・インコーポレイテッド | 炭素環及びヘテロ環で置換されたセミカルバゾン及びチオセミカルバゾン、及びその使用 |
| ES2352739T3 (es) | 1997-11-21 | 2011-02-22 | Purdue Neuroscience Company | 2-aminoacetamidas sustituidas y el uso de las mismas. |
| US6281211B1 (en) | 1999-02-04 | 2001-08-28 | Euro-Celtique S.A. | Substituted semicarbazides and the use thereof |
| ATE467620T1 (de) | 1999-03-26 | 2010-05-15 | Euro Celtique Sa | Arylsubstituierte pyrazole, imidazole, oxazole, thiazole und pyrrole, sowie deren verwendung |
| DK1169060T3 (da) | 1999-04-09 | 2006-01-16 | Euro Celtique Sa | Natriumkanalblokkerpræparater og anvendelse deraf |
| US7087597B1 (en) * | 1999-10-12 | 2006-08-08 | Takeda Pharmaceutical Company Limited | Pyrimidine 5-carboxamide compounds, process for producing the same and use thereof |
| AR029489A1 (es) | 2000-03-10 | 2003-07-02 | Euro Celtique Sa | Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento |
| CN1321112C (zh) | 2000-03-24 | 2007-06-13 | 欧洲凯尔特股份有限公司 | 作为钠通道阻滞剂的芳基取代的吡唑、三唑和四唑化合物 |
| US6335354B2 (en) | 2000-03-31 | 2002-01-01 | Cocensys Inc. | Aminopyridines and methods of using thereof |
| IL159765A0 (en) | 2001-07-16 | 2004-06-20 | Euro Celtique Sa | Aryl substituted thiazolidinone derivatives and pharmaceutical compositions containing the same |
| AR037233A1 (es) | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento |
| AR036873A1 (es) | 2001-09-07 | 2004-10-13 | Euro Celtique Sa | Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento |
| KR20040099324A (ko) | 2002-03-13 | 2004-11-26 | 유로-셀티큐 에스.에이. | 아릴 치환된 피리미딘 및 이것의 용도 |
| KR20050026031A (ko) | 2002-07-31 | 2005-03-14 | 유로-셀티큐 에스.에이. | 아릴 치환된 벤즈이미다졸 및 나트륨 채널 차단제로서이의 용도 |
| CN1671387A (zh) | 2002-07-31 | 2005-09-21 | 欧洲凯尔特股份有限公司 | 芳基取代的乙内酰脲化合物及其作为钠通道阻滞剂的应用 |
| US20040152696A1 (en) | 2002-08-01 | 2004-08-05 | Euro-Celtique S.A. | 2-substituted bicyclic benzoheterocyclic compounds and their use as sodium channel blockers |
| WO2005014849A2 (en) | 2003-07-03 | 2005-02-17 | Euro-Celtique, S.A. | Genes associated with responses to neuropathic pain |
| JP2008519034A (ja) * | 2004-11-03 | 2008-06-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネル調節剤としてのピリミジン誘導体および使用方法 |
| WO2007148185A2 (en) * | 2006-06-21 | 2007-12-27 | Pfizer Products Inc. | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors |
| EP2225223B1 (de) * | 2007-11-22 | 2017-01-11 | Boehringer Ingelheim International GmbH | Organische verbindungen |
| WO2010022055A2 (en) * | 2008-08-20 | 2010-02-25 | Amgen Inc. | Inhibitors of voltage-gated sodium channels |
| JP5685203B2 (ja) | 2009-05-29 | 2015-03-18 | ラクオリア創薬株式会社 | カルシウムチャネル遮断薬またはナトリウムチャネル遮断薬としてのアリール置換カルボキサミド誘導体 |
| WO2011103196A1 (en) * | 2010-02-17 | 2011-08-25 | Amgen Inc. | Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain |
| WO2011105572A1 (ja) * | 2010-02-26 | 2011-09-01 | 持田製薬株式会社 | 新規ヘテロアリール誘導体 |
| WO2011141474A1 (en) * | 2010-05-12 | 2011-11-17 | Boehringer Ingelheim International Gmbh | Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| WO2011158108A2 (en) | 2010-06-16 | 2011-12-22 | Purdue Pharma L.P. | Aryl substituted indoles and the use thereof |
| EP2593434A1 (en) | 2010-07-16 | 2013-05-22 | Purdue Pharma LP | Pyridine compounds as sodium channel blockers |
| AU2011303597A1 (en) | 2010-09-17 | 2013-04-11 | Purdue Pharma L.P. | Pyridine compounds and the uses thereof |
| WO2012046132A1 (en) | 2010-10-05 | 2012-04-12 | Purdue Pharma L.P. | Quinazoline compounds as sodium channel blockers |
| KR20130119964A (ko) | 2010-12-22 | 2013-11-01 | 퍼듀 퍼머 엘피 | 나트륨 채널 차단제로서의 치환된 피리딘 |
| US9226929B2 (en) | 2011-03-02 | 2016-01-05 | Bayer Intellectual Property Gmbh | Pharmaceutically active disubstituted triazine derivatives |
| WO2012135697A2 (en) | 2011-03-30 | 2012-10-04 | H. Lee Moffitt Cancer Center & Research Institute Inc. | Novel rho kinase inhibitors and methods of use |
| EP2753606B1 (en) | 2011-09-02 | 2017-07-05 | Purdue Pharma LP | Pyrimidines as sodium channel blockers |
| AU2012321111A1 (en) | 2011-10-31 | 2013-05-16 | Purdue Pharma L.P. | Quaternized amines as sodium channel blockers |
| US9181185B2 (en) | 2011-10-31 | 2015-11-10 | Purdue Pharma L.P. | Heteroaryl compounds as sodium channel blockers |
| US9133131B2 (en) | 2011-11-15 | 2015-09-15 | Purdue Pharma L.P. | Pyrimidine diol amides as sodium channel blockers |
| AU2013203824A1 (en) | 2012-03-16 | 2013-10-03 | Purdue Pharma L.P. | Substituted pyridines and pryimidines as sodium channel blockers |
| US9714252B2 (en) | 2012-12-20 | 2017-07-25 | Purdue Pharma L.P. | Cyclic sulfonamides as sodium channel blockers |
| US9120786B2 (en) | 2013-03-04 | 2015-09-01 | Purdue Pharma, L.P. | Triazine carboxamides as sodium channel blockers |
| ES2680246T3 (es) | 2013-03-04 | 2018-09-05 | Purdue Pharma Lp | Pirimidincarboxamidas como bloqueantes de canal de sodio |
| CA3082427A1 (en) | 2013-03-15 | 2014-09-25 | Purdue Pharma L.P. | Carboxamide derivatives and use thereof |
| US9359330B2 (en) | 2013-08-26 | 2016-06-07 | Purdue Pharma L.P. | Substituted piperidines as sodium channel blockers |
| US9828348B2 (en) | 2013-11-08 | 2017-11-28 | Purdue Pharma L.P. | Benzimidazole derivatives and use thereof |
| US9340504B2 (en) | 2013-11-21 | 2016-05-17 | Purdue Pharma L.P. | Pyridine and piperidine derivatives as novel sodium channel blockers |
| US9695144B2 (en) | 2013-12-23 | 2017-07-04 | Purdue Pharma L.P. | Dibenzazepine derivatives and use thereof |
| US10730866B2 (en) | 2014-04-07 | 2020-08-04 | Purdue Pharma L.P. | Indole derivatives and use thereof |
-
2015
- 2015-02-12 JP JP2016551246A patent/JP6556154B2/ja active Active
- 2015-02-12 AU AU2015217185A patent/AU2015217185B2/en active Active
- 2015-02-12 US US15/118,563 patent/US10738026B2/en active Active
- 2015-02-12 WO PCT/US2015/015576 patent/WO2015123398A1/en not_active Ceased
- 2015-02-12 EP EP15748728.1A patent/EP3105217B1/en active Active
- 2015-02-12 CA CA2939501A patent/CA2939501C/en active Active
- 2015-02-12 CN CN201580015712.3A patent/CN106103422B/zh not_active Expired - Fee Related
-
2016
- 2016-08-11 IL IL247252A patent/IL247252B/en not_active IP Right Cessation
-
2020
- 2020-08-06 US US16/986,901 patent/US11401258B2/en active Active